Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | September 02, 2026 | September 04, 2026 |
| Schrodinger, Inc.SDGR · Entity 4667 | Director | June 22, 2026 | June 23, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,686 |
Last balance in matching sequence
After 2026-09-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-02 · Sale · Disposed 10,824 · Balance 20,301 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 6,408 Unvested RSUs. Row 2 · 2026-09-02 · Sale · Disposed 615 · Balance 19,686 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 6,408 Unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 6,408 Unvested RSUs.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Schrodinger, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,388 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 8,141 · Balance 25,388 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events. F2: Includes 8,141 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2036-06-22 | Direct | 13,313 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 13,313 · Balance 13,313 F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events.
F2: Includes 8,141 unvested RSUs.
F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,109 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Grant · Acquired 472 · Balance 2,507 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-01 · Disposition to issuer · Disposed 398 · Balance 2,109 F2: Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30 | Direct | 1,433 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 1,433 · Balance 1,433 F3: Fully vested. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 398 |
Reported balance
After 2026-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-01 · Grant · Acquired 398 · Balance 398 F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death. F2: Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2: Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units.
F3: Fully vested.
F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 21:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 615 | $23.74 | $14,600.10 |
DisclosureSEC source: 0001797826-26-000006 · wk-form4_1788555742.xml · nonDerivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,686 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 6,408 Unvested RSUs. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,824 | $22.85 | $247,328.40 |
DisclosureSEC source: 0001797826-26-000006 · wk-form4_1788555742.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,301 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 6,408 Unvested RSUs. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 13,313 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0001797826-26-000003 · wk-form4_1782246516.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,313 Underlying: Common Stock · 13,313 shares Expires 2036-06-22 F3 · derivative.exercise_date: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 8,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001797826-26-000003 · wk-form4_1782246516.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,388 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events. F2 · balance_after: Includes 8,141 unvested RSUs. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 19,226 | $0.00 Strike: $19.66 | $0.00 |
DisclosureSEC source: 0001797826-26-000002 · wk-form4_1780692307.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,226 Underlying: Common Stock · 19,226 shares Expires 2036-06-03 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001797826-26-000002 · wk-form4_1780692307.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,125 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,408 unvested RSUs. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-26-000191 · wk-form4_1778017046.xml · derivative · entry 4 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398 Underlying: Common Stock · 398 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units. F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death. F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,433 | $0.00 Strike: $424.45 | $0.00 |
DisclosureSEC source: 0000875320-26-000191 · wk-form4_1778017046.xml · derivative · entry 3 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433 Underlying: Common Stock · 1,433 shares Expires 2036-04-30 F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000875320-26-000191 · wk-form4_1778017046.xml · nonDerivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,109 F2 · price: Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| May 01, 2026 Filed May 5, 2026 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 472 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000191 · wk-form4_1778017046.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,507 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:32 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 9,341 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001490978-25-000088 · wk-form4_1750451543.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,341 Underlying: Common Stock · 9,341 shares Expires 2035-06-18 F3 · derivative.exercise_date: The option was granted on June 18, 2025 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:32 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 5,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-25-000088 · wk-form4_1750451543.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,247 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2025 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events. F2 · balance_after: Includes 5,997 unvested RSUs. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 18,111 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001714899-25-000137 · wk-form4_1749154899.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2035-06-03 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000137 · wk-form4_1749154899.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,717 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,037 unvested RSUs. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,199 | $0.00 Strike: $502.97 | $0.00 |
DisclosureSEC source: 0000875320-25-000188 · wk-form4_1746478751.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,199 Underlying: Common Stock · 1,199 shares Expires 2035-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000188 · wk-form4_1746478751.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,035 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:17 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 8,550 | $0.00 Strike: $19.32 | $0.00 |
DisclosureSEC source: 0001490978-24-000056 · wk-form4_1718914649.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,550 Underlying: Common Stock · 8,550 shares Expires 2034-06-18 F3 · derivative.exercise_date: The option was granted on June 18, 2024. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:17 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-24-000056 · wk-form4_1718914649.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2024 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 5,000 unvested RSUs. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,901 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001714899-24-000141 · wk-form4_1717540348.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000141 · wk-form4_1717540348.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,680 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6595 unvested RSUs. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,571 | $0.00 Strike: $399.71 | $0.00 |
DisclosureSEC source: 0000875320-24-000131 · wk-form4_1714767803.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,571 Underlying: Common Stock · 1,571 shares Expires 2034-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 501 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000131 · wk-form4_1714767803.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,637 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,136 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-23-000052 · wk-form4_1701896824.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,136 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:01 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $45.26 | $0.00 |
DisclosureSEC source: 0001490978-23-000081 · wk-form4_1686949266.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option was granted on June 15, 2023. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:01 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-23-000081 · wk-form4_1686949266.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 15, 2023 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2 · balance_after: Includes 6,250 unvested RSUs. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000101 · wk-form4_1686002897.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000101 · wk-form4_1686002897.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,713 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,472 unvested RSUs. Read SEC document |
| May 22, 2023 Filed May 23, 2023 21:05 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 14,850 | $0.00 Strike: $11.52 | $0.00 |
DisclosureSEC source: 0001490978-23-000050 · wk-form4_1684875940.xml · derivative · entry 3 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,020 Underlying: Common Stock · 14,850 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · derivative.exercise_date: The option was granted on December 2, 2019. The shares underlying the option vested with respect to 25% of the shares on December 2, 2020 and the remainder vest in equal monthly installments through December 2, 2023. Read SEC document |
| May 22, 2023 Filed May 23, 2023 21:05 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 14,850 | $35.00 | $519,750.00 |
DisclosureSEC source: 0001490978-23-000050 · wk-form4_1684875940.xml · nonDerivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| May 22, 2023 Filed May 23, 2023 21:05 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 14,850 | $11.52 | $171,072.00 |
DisclosureSEC source: 0001490978-23-000050 · wk-form4_1684875940.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 21:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 4,950 | $0.00 Strike: $11.52 | $0.00 |
DisclosureSEC source: 0001209191-22-045632 · doc4.xml · derivative · entry 3 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,870 Underlying: Common Stock · 4,950 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · derivative.exercise_date: The option was granted on December 2, 2019. The shares underlying the option vested with respect to 25% of the shares on December 2, 2020 and the remainder vest in equal monthly installments through December 2, 2023. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 21:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 4,950 | $35.00 | $173,250.00 |
DisclosureSEC source: 0001209191-22-045632 · doc4.xml · nonDerivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 21:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 4,950 | $11.52 | $57,024.00 |
DisclosureSEC source: 0001209191-22-045632 · doc4.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:01 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 14,907 | $0.00 Strike: $24.51 | $0.00 |
DisclosureSEC source: 0001209191-22-037491 · doc4.xml · derivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 Underlying: Common Stock · 14,907 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option was granted on June 15, 2022. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,959 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000091 · wf-form4_165456044113456.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000091 · wf-form4_165456044113456.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,497 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 7,870 unvested restricted stock units. Read SEC document |
| January 08, 2022 Filed Jan 12, 2022 00:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 627 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000015 · wf-form4_164194885494715.xml · nonDerivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511 F1 · balance_after: The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 1884 previously reported restricted stock units and 627 shares acquired pursuant to vesting of restricted stock units. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:01 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 8,736 | $0.00 Strike: $76.08 | $0.00 |
DisclosureSEC source: 0001209191-21-042102 · doc4.xml · derivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,736 Underlying: Common Stock · 8,736 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option was granted on June 17, 2021. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 23:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 2,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-003305 · doc4.xml · derivative · entry 2 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511 Underlying: Common Stock · 2,511 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 8, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date. F3 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 8, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 23:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 7,535 | $0.00 Strike: $80.03 | $0.00 |
DisclosureSEC source: 0001209191-21-003305 · doc4.xml · derivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,535 Underlying: Common Stock · 7,535 shares Expires 2031-01-07 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 8, 2022, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 21:07 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 12,909 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003795 · doc4.xml · derivative · entry 1 Thornberry Nancy · CIK 0001797826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,909 Underlying: Common Stock · 12,909 shares Expires 2030-02-04 F1 · derivative.exercise_date: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.